文献速递消化道肿瘤放疗放疗物理与技术

SPARC:胰腺癌术前边缘强化立体定向放疗I期试验

SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer.
PubMed 文献 · Radiother Oncol · 2020-11-18

SPARC是一项前瞻性多中心I期滚动六剂量递增研究,针对临界可切除胰腺癌(BRPC)患者行术前五分割立体定向体部放疗(SBRT),对原发肿瘤和血管接触区域分别给予处方剂量。

要点

  • BRPC术前五分割SBRT从30 Gy/45 Gy递增至32.5 Gy/47.5 Gy未遇DLT。
  • MTD未确定,仅2例后续接受手术切除。

核心结论

  • 两个测试剂量水平的SBRT毒性低,但MTD未确定。
  • SBRT后仅少数患者接受胰腺肿瘤切除,难以就联合治疗的安全性得出结论。

研究设计与样本

  • 前瞻性多中心I期滚动六剂量递增研究,针对BRPC患者行术前五分割SBRT。
  • 原发肿瘤一个剂量、肿瘤与血管接触区域整合推量,起始剂量30 Gy至原发PTV、45 Gy至推量体积PTV_R。
  • 主要终点为MTD,定义为3例中0例或6例中1例出现DLT的最高剂量。

主要发现

  • 剂量从起始水平递增一级(处方32.5 Gy PTV、47.5 Gy PTV_R)未遇到任何DLT。
  • 发生9起严重不良反应或事件(7起CTCAE 3级、2起4级)。
  • 2例患者后续接受手术切除。
  • SBRT患者中位总生存期为8.1个月。

关键数值与推荐

  • 起始剂量:30 Gy至原发PTV、45 Gy至推量体积PTV_R,五次日分割。
  • 递增后剂量:32.5 Gy至PTV、47.5 Gy至PTV_R,未遇DLT。
  • MTD定义:3例中0例或6例中1例出现DLT的最高剂量。

临床怎么用

  • BRPC术前五分割SBRT在测试的两个剂量水平耐受性良好,但MTD未确立,尚不能据此确定推荐剂量。
  • SBRT后转为手术切除的比例低,联合治疗的安全性需进一步研究。

局限性

  • MTD未确定,仅测试了两个剂量水平。
  • 仅2例后续接受手术,难以评估SBRT与手术联合的安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk. MATERIALS AND METHODS: We conducted a prospective multicentre phase-1 rolling-six dose-escalation study. BRPC patients received pre-operative SBRT, with one dose to the primary tumour and an integrated boost to the region where tumour was in contact with vasculature. Four dose-levels were proposed, with starting dose 30 Gy to primary PTV and 45 Gy to boost volume (PTV_R), in five daily fractions. Primary endpoint was maximum tolerated dose (MTD), defined as highest dose where zero of three or one of six patients experienced dose-limiting toxicity (DLT). RESULTS: Twelve patients were registered, eleven received SBRT. Radiotherapy was well tolerated with all treatment completed as scheduled. Dose was escalated one level up from starting dose without encountering any DLT (prescribed 32.5 Gy PTV, 47.5 Gy PTV_R). Nine serious adverse reactions or events occurred (seven CTCAE Grade 3, two Grade 4). Two patients went on to have surgical resection. Median overall survival for SBRT patients was 8.1 months. The study closed early when it was unable to recruit to schedule. CONCLUSION: Toxicity of SBRT was low for the two dose-levels that were tested, but MTD was not established. Few patients subsequently underwent resection of pancreatic tumour after SBRT, and it is difficult to draw conclusions regarding the safety or toxicity of these therapies in combination.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Holyoake DLP, Robinson M, Silva M, et al. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiother Oncol. 2020. PMID: 33217498. doi:10.1016/j.radonc.2020.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。